Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Item

http://www.wikidata.org/entity/Q30625695

Q30625695

about

Bevacizumab treatment for advanced breast cancer Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.Recombinant human VEGF165b inhibits experimental choroidal neovascularization The VEGF family in cancer and antibody-based strategies for their inhibition.Targeted therapies for pancreatic cancer.Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.Present and future evolution of advanced breast cancer therapy.Application of quantitative pharmacology in development of therapeutic monoclonal antibodies New approaches in angiogenic targeting for colorectal cancer.Targeting angiogenesis in advanced cervical cancer.Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.Targeted therapies in the management of renal cell carcinoma: role of bevacizumab The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials.Napoleone Ferrara and the saga of vascular endothelial growth factor.Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.Therapies directed at vascular endothelial growth factor.Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Targeting angiogenesis in esophagogastric adenocarcinoma.Tyrosine kinase inhibitors as cancer therapy.Angiogenesis inhibitors in clinical development; where are we now and where are we going?Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer Molecular-targeted agents in pancreatic cancer.Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.Progress report on the potential of angiogenesis inhibitors for neuro-oncology.Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Bevacizumab--current status and future directions.Therapeutic targeting of receptor tyrosine kinases in lung cancer.Anti-VEGF therapies in the clinic

P2860

Q27027498-1E839F7C-45F2-4BD2-9DE5-C2AD8A4E85BE Q30790872-498B483F-62E3-4961-BA61-FDBD3487BFF0 Q31157714-473C4BAA-081F-44D1-AA83-37B918EF8F92 Q33384793-8230AD52-922D-4A8B-9280-4929D4E2DC70 Q33397464-32FA80AA-D1E9-45D9-B1DF-C1E1D8779982 Q33440505-A28ECD71-3D7C-4D4E-9779-DF397BC8185A Q33541827-C904C241-8719-4DA2-A251-D39098733A34 Q33733437-AB772352-16A5-4605-B53A-C3BA3F6C6F17 Q33899923-DF314A5B-4E2B-45E7-9C73-B48236341E85 Q34225256-72F84186-15FE-41F2-83E1-6B8D7551C83E Q34274925-EAD98655-64FB-458F-8452-1B7676179E29 Q34293689-D9D159EF-8466-4E26-A79E-F58B9018BDDA Q34382785-34F2794B-0154-435D-B484-29DFC6377119 Q34389368-4E003B22-5AA7-405B-9F14-3725CD6C26F5 Q34417804-E512B0DC-E8A4-475B-B002-D1A03AD3F89C Q34450520-3C35844A-5442-4827-9605-66B3AE2DB644 Q34608643-A77716C8-5A4B-471A-9C84-03C810D32267 Q34611205-3414CBEC-67C3-4443-966A-919FF6D50B47 Q34773758-6E22EB5C-A4F9-41EA-9ED2-707ED053F742 Q34787946-7A647B5F-2F97-4DE9-8B0D-599925D66DE7 Q34951074-A7F2B9DA-F2AC-4CBB-A3F8-EBD363C37EA6 Q34974876-36571A56-B791-46FB-86CB-8EB5557D8317 Q35011885-7D3D3BF4-C030-484F-8E36-A493843A5B6B Q35076287-48DFB7E1-8ABB-4DEC-AD84-D47A30A85AC4 Q35164732-82FC17A3-C15F-4EA6-9C10-FCFDC37229A4 Q35584482-506E9592-BBC2-4BBD-83BE-6C0860E48210 Q35584958-B3FF6672-F185-44BF-BCEC-6A21556586F2 Q35589206-D8172B3A-2961-45F0-BE07-D4B0D5DCCFE8 Q35622433-4ACE1DDB-2F55-4454-8B78-EDBD808C6F06 Q35623279-1B39A47C-F2F2-41E3-A405-265C984E003A Q35641998-417F8737-E0C3-403F-B7D7-3050384991A6 Q35798814-EDFEBDD8-B516-4354-84B5-A557C1EF1A4E Q35813229-371C2EBF-CB01-4001-A03C-CDED50CD8EDB Q35913223-B16C5038-8E17-4E45-A060-8E3377DDA107 Q35964419-4BC6638D-0B00-43BB-AC35-B2142F696385 Q36089148-915695B3-A8A5-48C2-979C-516674D80450 Q36103026-0FCFD0AD-D3A2-48DE-B65C-FD6ED15AEAEB Q36154083-3588D733-685D-4545-B001-48B12BC1A01D Q36158717-84BC0B74-6F6F-4F93-AB51-1B9C83F39E4E Q36330281-6C0ED0CC-45B1-4899-9C39-CD6F5396F7B3

P2860

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

Item

http://www.wikidata.org/entity/Q30625695

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu